人胚胎干细胞来源视网膜色素上皮细胞移植治疗黄斑变性
这是一项1/2期开放标签剂量递增试验,纳入12例晚期Stargardt病(STGD1)患者,视网膜下移植最多200 000个人胚胎干细胞来源的视网膜色素上皮细胞,并全身免疫抑制治疗13周。结果显示移植区出现剂量依赖性视网膜下色素沉着,无失控增殖或炎症反应证据,但微视野检查在12个月时未显示获益,最高剂量1例出现局部视网膜变薄和敏感度下降。
要点
- 12例晚期STGD1患者接受视网膜下移植,所有患者移植区出现剂量依赖性视网膜下色素沉着且停用免疫抑制后持续存在。
- 未发现失控增殖或炎症反应证据,但微视野检查在12个月时未显示获益。
- 最高剂量1例出现色素沉着区局部视网膜变薄和敏感度下降,提示潜在 harm。
核心结论
- 视网膜下色素沉着与移植的人胚胎干细胞来源视网膜色素上皮细胞存活一致,但也可能反映细胞缺失时释放的色素。
- 研究结果表明详细分析视网膜结构与功能的空间相关性对确定细胞移植影响的价值,并提示早期疾病干预应谨慎。
- 鉴于晚期疾病进展缓慢,任何防止进一步恶化的保护作用可能需要更长观察期才能显现。
研究设计与样本
- 1/2期开放标签剂量递增试验(clinicaltrials.gov标识符NCT01469832),评估安全性和潜在疗效。
- 纳入12例晚期Stargardt病(STGD1)患者。
- 视网膜下移植最多200 000个人胚胎干细胞来源的视网膜色素上皮细胞,并全身免疫抑制治疗13周。
主要发现
- 所有参与者移植区出现剂量依赖性视网膜下色素沉着,停用全身免疫抑制后持续存在。
- 未发现失控增殖或炎症反应证据。
- 4例最佳矫正视力边缘改善,但未持续或与未治疗对侧眼相似改善相匹配。
- 微视野检查在12个月时12例参与者中未显示获益证据。
- 最高剂量1例出现色素沉着区局部视网膜变薄和敏感度下降,提示潜在 harm。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area. DESIGN: Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832). PARTICIPANTS: Twelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults. METHODS: Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks. MAIN OUTCOME MEASURES: The primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT. RESULTS: Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function Questionnaire indicated no significant change. CONCLUSIONS: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity the impact of cell transplantation and suggest that intervention in early stage of disease should be approached with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection against further deterioration may be evident only after a more extended period of observation.
引用
- Mehat MS, Sundaram V, Ripamonti C, et al. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration. Ophthalmology. 2018. PMID: 29884405. doi:10.1016/j.ophtha.2018.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。